Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept for moderate to severe active systemic lupus erythematosus – lymphocyte subset effects
ChiCTR2400086874Phase 4Completed
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Jul 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telitacicept in systemic lupus erythematosus (SLE), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: SLE Responder Index (SRI-4) response rate at Week 24. Started Jul 2024; status: completed.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2400086874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086874.